Financial Post EN

Pfizer Says Long-Awaited Lyme Vaccine Was Effective in Study

Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, though fewer-than-expected cases in a study made it hard to determine how well it works on a large scale.

Mar 23, 2026 &03182323202631; 11:18 UTC financialpost.com Trending 3/5

Read original on financialpost.com ↗

→

Neutral impact

Sentiment score: +15/100

Moderate impact Medium-term (weeks)

WHAT THIS MEANS

Pfizer announced 73% efficacy for its experimental Lyme disease vaccine in clinical trials, though the study was underpowered due to fewer-than-expected cases, limiting confidence in real-world effectiveness at scale. This represents progress on a long-awaited therapeutic but falls short of the clarity needed for strong market enthusiasm.

AI CONFIDENCE

72% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

⇅

PFE

PFEStock

High volatility expected

Positive efficacy data supports pipeline value, but underpowered study design and 73% efficacy (below typical vaccine benchmarks) limit upside catalyst strength. Regulatory approval timeline remains uncertain.

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Monitor for FDA feedback and Phase 3 trial design details before positioning. The underpowered study is a red flag—wait for larger, adequately-powered trials before treating this as a meaningful growth catalyst. Current headline likely already priced into PFE; no immediate trade signal warranted.

KEY SIGNALS

Clinical trial efficacy announced but study underpowered73% efficacy below market expectations for modern vaccinesRegulatory pathway clarity still pendingLong development timeline suggests limited near-term revenue impactLyme disease market size modest relative to Pfizer's portfolio

SECTORS INVOLVED

HealthcarePharmaceuticalsBiotechnology

Analysis generated on Mar 23, 2026 at 11:21 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Financial Post. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Pfizer Says Long-Awaited Lyme Vaccine Was Effective in Study

RELATED INTELLIGENCE